Co-morbid diabetes in patients with Crohn's disease predicts a greater need for surgical intervention

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 1, 2012, Pages 126-132

  Harper, J W ^a   Welch, M P ^a   Sinanan, M N ^b   Wahbeh, G T ^b   Lee, S D ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB;

ADULT; ANUS DISEASE; ARTICLE; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DRUG USE; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; ILEUM DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SURGICAL RISK;

ADULT; COHORT STUDIES; COMORBIDITY; CROHN DISEASE; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK; TIME FACTORS;

EID: 83555168217     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04915.x     Document Type: Article

References (29)

1. Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-90. (Pubitemid 37430605)
2. Fox CS, Pencina MJ, Meigs JB, et al. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation 2006; 113: 2914.
3. Falanga V,. Chronic wounds: pathophysiologic and experimental considerations. J Invest Dermatol 1993; 100: 721-5. (Pubitemid 23128373)
4. Loots MA, Lamme EN, Zeegelaar J, et al. Differences in cellular infiltrate and extracellular matrix of chronic diabetic and venous ulcers versus acute wounds. J Invest Dermatol 1998; 111: 850-7. (Pubitemid 28509329)
5. Herrick SE, Sloan P, McGurk M, et al. Sequential changes in histologic pattern and extracellular matrix deposition during the healing of chronic venous ulcers. Am J Pathol 1992; 141: 1085-95.
6. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 8-15.
7. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50. (Pubitemid 34784976)
8. Penner RM, Madsen KL, Fedorak RN,. Postoperative Crohn's disease. Inflamm Bowel Dis 2005; 11: 765-77. (Pubitemid 41271182)
9. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9. (Pubitemid 34621118)
10. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
11. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn's disease. Gastroenterology 2006; 130: 650-6. (Pubitemid 43374514)
12. Burner TW, Rosenthal AK,. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009; 21: 50-4.
13. Del Rosso A, Cerinic MM, De Giorgio F, et al. Rheumatological manifestations in diabetes mellitus. Curr Diabetes Rev 2006; 2: 455-66. (Pubitemid 44734230)
14. Taxonera C, Rodrigo L, Casellas F, et al. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease. J Clin Gastroenterol 2009; 43: 950-6.
15. Rubenstein JH, Chong RY, Cohen RD,. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol 2002; 35: 151-6. (Pubitemid 34815854)
16. Picco MF, Zubiaurre I, Adluni M, et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-9.
17. D'Haens GR,. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol 2010; 7: 86-92.
18. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994; 106: 643-8. (Pubitemid 24064330)
19. Hamon JF, Carbonnel F, Beaugerie L, et al. Comparison of long-term course of perforating and non-perforating Crohn disease. Gastroenterol Clin Biol 1998; 22: 601-6. (Pubitemid 28385603)
20. Hofer B, Bottger T, Hernandez-Richter T, et al. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn's disease. Hepatogastroenterology 2001; 48: 152-5. (Pubitemid 32226093)
21. Borley NR, Mortensen NJ, Chaudry MA, et al. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum 2002; 45: 377-83. (Pubitemid 34273620)
22. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30. (Pubitemid 44085679)
23. Bernell O, Lapidus A, Hellers G,. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38.
24. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006; 101: 360-7. (Pubitemid 43381681)
25. Xu H, Sethi JK, Hotamisligil GS,. Transmembrane tumor necrosis factor (TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1. J Biol Chem 1999; 274: 26287-95.
26. Hotamisligil GS, Budavari A, Murray D, et al. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 1994; 94: 1543-9.
27. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-15.
28. Araujo EP, De Souza CT, Ueno M, et al. Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes. Endocrinology 2007; 148: 5991-7. (Pubitemid 350146162)
29. Seriolo B, Ferrone C, Cutolo M,. Longterm anti-tumor necrosis factor-alpha treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol 2008; 35: 355-7. (Pubitemid 351281162)